18,313 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 18,313 shares of the medical equipment provider’s stock, valued at approximately $1,934,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dunhill Financial LLC raised its position in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the last quarter. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet in the 4th quarter valued at $25,000. Brooklyn Investment Group bought a new position in Zimmer Biomet in the 3rd quarter valued at $35,000. Kentucky Trust Co bought a new position in Zimmer Biomet in the 4th quarter valued at $39,000. Finally, OFI Invest Asset Management bought a new position in Zimmer Biomet in the 4th quarter valued at $40,000. Institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ZBH shares. Raymond James lowered their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. JMP Securities reissued a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Stifel Nicolaus lifted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada lowered their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $124.15.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.95% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH stock opened at $110.79 on Friday. The business’s 50-day moving average price is $106.74 and its two-hundred day moving average price is $106.93. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market cap of $22.05 billion, a PE ratio of 24.90, a P/E/G ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm earned $2.20 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.